Choroidal vascularity index after a single dose of intravitreal dexamethasone implant in patients with refractory diabetic macular edema
 
Yazarlar (5)
Doç. Dr. Özkan KOCAMIŞ Kırşehir Ahi Evran Üniversitesi, Türkiye
Emine Temel
Kırşehir Ahi Evran Üniversitesi, Türkiye
Gökçen Özcan
Kırşehir Ahi Evran Üniversitesi, Türkiye
Nazife Aşıkgarip
Kırşehir Ahi Evran Üniversitesi, Türkiye
Prof. Dr. Kemal ÖRNEK Kırşehir Ahi Evran Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Photodiagnosis and Photodynamic Therapy (Q3)
Dergi ISSN 1572-1000 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 09-2022
Kabul Tarihi 12-04-2026 Yayınlanma Tarihi
Cilt / Sayı / Sayfa 39 / 1 / 102996–0 DOI 10.1016/j.pdpdt.2022.102996
Makale Linki https://www.sciencedirect.com/science/article/abs/pii/S1572100022002824?via%3Dihub
Özet
PurposeTo evaluate choroidal vascularity index (CVI) after a single dose of intravitreal dexamethasone implant in refractory diabetic macular oedema (DME).MethodsTotal choroidal area, luminal area, and CVI were measured at baseline, 1st month, and at 3rd month after dexamethasone implant using binarization of enhanced depth imaging optical coherence tomography (EDI-OCT) images.ResultsA total of 25 eyes of 25 patients (mean age: 61.4 ± 8.3 years; 12 males, 13 females), were enroled in the study. All eyes had been previously treated with intravitreal aflibercept injections (mean number of injections 4.6 ± 2.5). Mean CVI was 70.3 ± 8.1 prior to intravitreal dexamethasone treatment. It was decreased to 66.1 ± 9.3 at 1 month and 63.5 ± 10.1 at 3 months after treatment. The mean CVI was significantly decreased at 3 months compared with pre-treatment measures (p = 0.033).ConclusionCVI was found to be …
Anahtar Kelimeler
Aflibercept | Choroidal vascularity index | Dexamethasone | Diabetic macular oedema | Enhanced depth-optical coherence tomography